FLIR Systems Announces Four New Exx-Series Handheld Thermal Imaging Cameras
FLIR Systems, Inc. (NASDAQ: FLIR) today announced four new additions to its Exx-Series of advanced thermal imaging cameras: the E96, E86, E76 and E54. Compared to predecessor Exx-Series cameras, the new cameras offer enhanced thermal resolution for more vibrant, easy-to-read images and on-camera routing capability to improve field survey efficiency. The new Exx-Series cameras are designed to help professionals detect the early signs of building issues, identify hot spots, troubleshoot electrical and mechanical systems, and prevent problems before they cause damage that leads to expensive repairs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005252/en/
The FLIR E96 camera with on-camera routing capability, combined with FLIR Thermal Studio Pro software is used to identify mechanical issues on a factory floor. (Photo: Business Wire)
The E96, with a 640x480 resolution and eight-times digital zoom, is the most advanced Exx-Series thermal camera to date. It delivers improved measurement results over the greatest distance to target, so professionals can safely diagnose electrical faults or locate hidden anomalies at very high temperatures up to 1500 degrees Celsius (2732 degrees Fahrenheit), including in harsh industrial environments such as steel mills or kilns, to help keep the workplace running smoothly.
For the first time, FLIR Inspection Route is now offered as a standard feature on every Exx-Series camera and is complemented by the FLIR Thermal Studio Pro software with Route Creator plugin, sold separately as an annual subscription. The complete routing bundle enables professionals to create and export custom inspection and pre-planned routes, ideal for large or multi-location electrical or mechanical projects.
“The new Exx-Series advanced thermal imaging cameras enable building professionals, inspectors, engineers, researchers, and facility maintenance personnel to do more than ever before with a handheld thermal camera,” said Rickard Lindvall, General Manager, Solutions Business at FLIR. “With improved thermal resolution and on-camera routing capabilities, the Exx Series can help our customers make better, informed decisions to complete the job more efficiently and effectively.”
The E96, E86, and E76 include UltraMax® high-definition image enhancement technology and improved contrast with one-touch level and spanning functions to view greater image details. In addition, interchangeable AutoCal™ lenses offer complete coverage of near and distance targets, with the built-in laser distance meter ensuring the crisp focus needed for accurate temperature measurement.
The new Exx-Series cameras are available globally starting today through authorized dealers and FLIR.com. To learn more about FLIR Systems’ entire Exx-Series line, visit: www.flir.com/exx-series.
Through March 31, 2021, customers who purchase an Exx-Series camera will receive a free three-month Thermal Studio Pro and Route Creator trial bundle. The FLIR Thermal Studio Suite is also available separately through an annual subscription in Standard and Pro versions, while the Starter version is offered at no charge. To learn more about FLIR Thermal Studio Suite, visit www.flir.com/thermal-studio-suite.
About FLIR Systems, Inc .
Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense and industrial applications. FLIR Systems’ vision is to be “The World’s Sixth Sense," creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit www.flir.com and follow @flir.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005252/en/
Contact information
Media Relations:
Eleana Stayer
Phone: +44 7545 204375.
Email: eleana.stayer@flir.com
Investor Relations:
Lasse Glassen
Addo Investor Relations
Phone: 424-238-6249
Email: Investors@flir.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom